Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

992.18 +4.91 (+0.50%)
Streaming Delayed Price Updated: 11:25 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
36 37 Next >
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
Via Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
7 Low Volatility Stocks to Buy Right Now for Steady Returns
A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases. 
Via InvestorPlace
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. 
Via InvestorPlace
S&P 500 Slips Further into Correction Territory as Stocks Give Up Gains
Stocks have pulled back from this morning's gains, amid the ongoing Russia-Ukraine border crisis, with all three benchmarks looking to extend their losing streaks. 
Via Talk Markets
Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired
Kodiak hoped a less frequent dosing plan would benefit patients with an eye disease. 
Via Investor's Business Daily
Why Kodiak Sciences Shares Are Plunging Today
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-... 
Via Benzinga
Is Moderna the Next Gilead or the Next Regeneron?
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed. 
Via InvestorPlace
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)  
Via Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
The  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading. 
Via Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. 
Via Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
The major indexes slashed weekly gains after Monday's follow-through day. 
Via Investor's Business Daily
Regeneron Scores Quarterly Beat On Covid Cocktail — But Future Sales Are Shaky
Regeneron posted 104% sales growth, including $2.3 billion from REGEN-COV. 
Via Investor's Business Daily
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned  
Via Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Recap: Regeneron Pharmaceuticals Q4 Earnings
  Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 4, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.